Young et al., 2020

Clinical evaluation of BD VeritorTM SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia® SARS Antigen point-of-care test.

Stephen Young, PhD, a# Stephanie Taylor, MD, b Catherine Cammarata, BS, b Celine Roger-

Dalbert, PhD, ^c Amanda Montano, BS, ^a Christen Griego-Fullbright, BS, ^a Cameron Burgard, BS, ^a

Catherine Fernandez, PhD, d Karen Eckert, MS, c Jeffrey C. Andrews, MD, Huimiao Ren, PhD, d

Joseph Allen, MD, e Ronald Ackerman, MD, f Charles K. Cooper, MD^{c##}

^aTricore Reference Laboratory, 1001 Woodward Place, N.E., Albuquerque, NM, USA

^bLouisiana State University Health Science Center, 533 Bolivar Street, Room 711, New Orleans,

LA, USA

^cBecton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, 7

Loveton Circle, Sparks, MD, USA

^dBecton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, 10865

Road to the Cure, San Diego, CA, USA

^eSTAT Research, 600 Aviator Court, Suite 100B, Vandalia, Ohio, USA

^fComprehensive Clinical Research, LLC., 603 Village Blvd., Suite 301 West Palm Beach, FL,

USA

Key words: COVID-19; SARS-CoV-2; Veritor test; Point-of-care, Sofia test

Running title: Veritor SARS-Cov-2 POC test

#To whom correspondence should be addressed:

Stephen Young, PhD

Title: Medical Director of Research and Clinical Trials

Address: 1001 Woodward Place, N.E. Albuquerque, NM 87102

Telephone: 505-938-8855

FAX:

Young et al., 2020

Email: Steve.Young@Tricore.org

##To whom alternate correspondence should be addressed:

Charles K. Cooper, MD

Title: Vice President for Medical Affairs, BD-IDS, BD Life Sciences

7 Loveton Circle, Sparks, MD, USA

Telephone: 410-316-4984

FAX:

Email: Charles_K_Cooper@bd.com

Summary (40 word limit): The BD Veritor SARS-Cov-2 antigen test met FDA-EUA acceptance criteria for SARS-CoV-2 antigen testing for subjects with COVID-19 symptoms (0-5 days after onset). BD Veritor and Quidel Sofia antigen tests had good agreement for SARS-CoV-2 detection; discordant analysis favored Veritor.

Young et al., 2020

ABSTRACT (264 words)

Objectives

The clinical performance of the BD Veritor™ System for Rapid Detection of SARS-CoV-2 antigen (Veritor test), a chromatographic immunoassay that detects the SARS-CoV-2 nucleocapsid antigen, was evaluated on nasal specimens from patients with suspected symptoms of COVID-19.

Methods and Materials

Two studies were employed. In study 1, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID-19 symptoms (≤7 days from symptom onset [DSO]), ≥18 years of age, were utilized to compare the Veritor test to the Lyra[®] SARS-CoV-2 PCR Assay (Lyra assay). In study 2, nasal specimens from 361 participants with COVID-19 symptoms (≤5 DSO), ≥18 years of age, were utilized to compare performance of the Veritor test to that of the Sofia[®] SARS Antigen FIA test ("Sofia test"). Positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) were the primary outcomes

Results

In study 1, the Veritor test had a PPA with the Lyra assay ranging from 81.8%-87.5% for the 0-1 through the 0-6 DSO ranges. In study 2, the Veritor test had a PPA, NPA, and OPA of 97.4%, 98.1%, and 98.1%, respectively with the Sofia test. Discordant testing showed one Lyra positive missed by the Veritor test and five Lyra positives missed by Sofia; one Veritor positive result was negative by Lyra.

Young et al., 2020

Conclusions

The Veritor test met FDA-EUA acceptance criteria for SARS-CoV-2 antigen testing (≥80% PPA point estimate) for the 0-5 and 0-6 DSO ranges. In addition, the Veritor and Sofia tests showed a high degree of agreement for detection of SARS-CoV-2. The Veritor test should facilitate rapid and reliable results for COVID-19 diagnosis.

Young et al., 2020

INTRODUCTION (332 words)

In response to the COVID-19 pandemic, an emphasis has been placed on SARS-CoV-2 diagnostic testing for symptomatic individuals.[1] Although laboratory-based PCR testing is considered the clinical reference standard for COVID-19 diagnosis, it is associated with some drawbacks, including false-negative reporting.[2-4] Also, limitations in capacity have been documented for PCR-based testing,[5, 6] which can lead to prolonged time to result (at best 24 hours when sample shipment is considered); and in most cases, dedicated staff and automated platforms are required to provide effective turn-around-time and optimized patient management.[7]

In February 2020, the World Health Organization identified point-of-care (POC) testing as a number one priority to address the COVID-19 pandemic.[8] The relatively small investment in resources and expertise required to perform POC testing makes it ideal for use in decentralized health care settings.[7] Antigen-based immunoassay POC tests for SARS-CoV-2 can target multiple viral antigens, including spike or nucleocapsid protein in a cartridge-based, lateral flow format. Although it is too early to determine whether one target is advantageous over another, evidence supports the efficacy of nucleocapsid detection in these types of antigen-based assays.[9, 10] Reports involving SARS and SARS-CoV-2 have demonstrated that the nucleocapsid protein is produced at high levels relative to the other viral proteins.[11, 12] In addition, nucleocapsid detection was recently shown, albeit in a serology-based test, to result in higher sensitivity for detection of SARS-CoV-2 compared to spike protein detection.[13]

Young et al., 2020

US-FDA Emergency Use Authorization (EUA) was recently granted for the BD Veritor™

System for Rapid Detection of SARS-CoV-2 (henceforth referred to as "Veritor test"), a POC, chromatographic immunoassay that detects the SARS-CoV-2 nucleocapsid antigen. This report presents the performance data for the Veritor test using nasal swab specimens from COVID-19 symptomatic individuals compared to the Lyra® SARS-CoV-2 Assay (henceforth referred to as "Lyra assay"), which was utilized as the clinical reference standard. In a sub-population, Veritor test results were compared with results from another FDA-EUA authorized nucleoprotein antigen test, the Quidel Sofia® SARS Antigen FIA test (henceforth referred to as "Sofia test").

Young et al., 2020

METHODS AND MATERIALS (934 words)

Study design

Both studies described here involved a prospective collection of upper respiratory specimens.

Eligible participants were ≥18 years of age and presented with one or more self-reported

COVID-19 signs or symptoms. Individuals were excluded if a nasal swab was collected as part

of standard of care (SOC). Demographic and healthcare-related information was collected (e.g.

symptomology, health history, etc.). No study procedures were performed without an informed

consent process or signature of a consent form. This research was performed in accordance with

Good Clinical Practice guidelines and the-Declaration of Helsinki. This article was prepared

according to STARD guidelines for diagnostic accuracy studies reporting.[14]

Specimen collection

Study 1 (EUA Veritor/Lyra comparison)

The first study was utilized to determine whether the Veritor test met FDA-EUA criteria for

detection of SARS-CoV-2 in COVID-19 symptomatic individuals (within ≤7 DSO). Collection

of specimens from 260 participants occurred across 21 geographically diverse study sites

between June 5-11, 2020. Specimens for the Veritor test were from clinician-collected nasal

specimens using regular-tipped flocked swabs (Becton, Dickinson and Company, BD Life

Sciences—Integrated Diagnostics Solutions, Sparks, MD, USA) inserted approximately 2.5 cm

up the nostril (from the edge of the nostril). The swab was rolled five times along the mucosa of

the nostril to ensure that sufficient mucus and cells were collected; the process was repeated in

7

the other nostril using the same swab.

Young et al., 2020

Lyra assay specimens came from nasopharyngeal (NP) or oropharyngeal (OP) swabs; SOC OP or NP swabs were taken before any study swabs. If an NP swab was collected as part of SOC, the participant had the option of having an OP study swab taken in lieu of a second NP swab.-All NP (n=217) or OP (n=34) specimens were clinician-collected. Reference testing was performed at TriCore Reference Laboratories while the Veritor testing was performed internally at BD (San Diego, CA, USA).

Study 2 (Veritor/Sofia comparison)

The second study involved comparison of Veritor test performance to the Sofia test for SARS-CoV-2 detection run with Sofia 2 analyzer. Collection occurred from 377 participants with symptoms of COVID-19 (≤5 DSO) from five study sites in the USA. Specimen collection for Veritor testing was performed as described above. For Sofia testing, clinician-collected nasal specimens occurred using methods and swabs described in the IFU (Puritan® regular foam swabs [Puritan, Guilford, ME, USA]). The specimens were obtained from a single nostril (with the most visible secretion) using gentle rotation. In some cases (n=76 specimens; approximately 20.2% of specimens in study 2), due to an update in the Sofia instructions for use (IFU), participants were instructed to blow their nose prior to nasal swab specimen collection. NP swab specimen collection for the Lyra assay (only for Veritor/Sofia discordant testing) was performed as described above. Testing for Veritor, Sofia2, and discordant Lyra assay, was performed at TriCore Reference Laboratories.

8

Test procedures

Young et al., 2020

Swabs were shipped for testing on dry ice (-70°C); nasal swabs were shipped dry and OP/NP swabs were shipped in universal viral transport medium. All testing was conducted with all personnel blinded to all other test results.

The Veritor and Sofia tests were performed according to the manufacturer's IFU (Becton, Dickinson and Company, BD Life Sciences—Integrated Diagnostic Solutions, San Diego, CA [15] and Quidel Corporation, Athens, OH,[16] respectively). Swabs were removed from -70°C storage ≤5 hours prior to the time of testing. Swabs were placed at 2-8°C for ≥2 hours and then at room temperature for 10-30 minutes prior to testing.

For specimen extraction prior to Veritor or Sofia testing, the swabs were added to each respective extraction buffer tubes and mixed for at least 15-30 seconds or 1 minute, respectively. The extraction buffer/specimen mixture from each test was then added to the sample well of the corresponding test cartridge to initiate the testing. After the assays proceeded for 15 minutes, the test cartridges were inserted into either the Veritor or Sofia 2 analyzer to obtain results.

The Lyra assay was performed according to the manufacturer's IFU (Quidel Corporation.

Athens, OH).[17] When using the NucliSENS® easyMAG® and the Applied Biosystem 7500

Fast Dx Real-Time PCR instrument, the Lyra assay reports cycle number in a manner that omits the first 10 cycles; here the cycle numbers for the Lyra assay are reported with the first 10 cycles included. The BD MAXTM real time SARS-CoV-2 PCR assay (henceforth termed "MAX assay") was used for discordant testing on residual nasal swabs following Veritor and Lyra testing in

Young et al., 2020

study 1. The MAX assay was performed according to the manufacturer's IFU (Becton,

Dickinson and Company, BD Life Sciences—Integrated Diagnostic Solutions, Sparks, MD).[18]

Data collection and statistical analyses

The primary outcome measures for this study were positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) point estimates for the Veritor test compared to results from the Lyra assay in study 1 and for the Veritor test compared to the Sofia test in study 2.

For study 1, the acceptance criteria was a point estimate of ≥80% PPA of the Veritor test when compared to the Lyra assay; clinical evaluation required contiguous enrolment to a minimum of 30 prospectively collected positive specimens as specified in the Antigen Template for Manufacturers (May 11, 2020) for EUA submissions to the US-FDA.[19] Based on an estimated 10% prevalence rate, it was necessary to enroll approximately 300 participants to achieve the required number of positives.

For study 1, positive predictive value, negative predictive value, and accuracy were also calculated as secondary outcomes.[20] Additionally, a t-test (2-tailed) was used to compare means between Lyra assay positive Ct values on specimens matched to Veritor negative and positive test results for SARS-CoV-2 in study 1.

Young et al., 2020

RESULTS (851 words)

Study 1 (EUA study)

Participant reconciliation, demographics, and COVID-19 symptomology

The mean and median age of the participants (44.7 and 43 years, respectively) were close (<u>Table S1</u>). More than half of the participants were female. By race, the largest proportion of participants were White, followed by Black, and then Asian. Approximately 40% were Hispanic or Latino. Cough was the most-reported symptom from participants, followed by muscle pain, and then headache. While the drive-through/tent and outpatient clinic collection site categories represented approximately three-fourths of the collection sites, the research clinic category had the highest positivity rate (22.2%). The mean for DSO among the participants was 3.2 (<u>Table S1</u>). From 260 participants, specimen sets from nine participants were removed overall. One was removed due to a labeling error, two sets were from participants with no COVID-19 symptoms, four sets had enrollment errors, and two had invalid reference results. Thus, 251 evaluable nasal specimens (each paired with either OP or NP specimens) were included (<u>Figure S1a</u>).

Veritor test performance and discordant reconciliation

Performance values for the Veritor test are shown by DSO for the participants providing valid specimens (<u>Table 1</u>). The 0-5 DSO range was the shortest range tested to have a PPA value above 80% and include at least 30 reference positive results. The 0-6 DSO range also met PPA value acceptance criteria. The NPA for the Veritor test was 100% for the 0-1 to 0-5 DSO ranges; however, the NPA value for the 0-6 and 0-7 DSO ranges was 99.5% (95% CI: 97.4, 99.9) (<u>Table 1</u>). The area under the curve (AUC) values associated with Veritor test performance for the 0-1 through the 0-6 DSO ranges were >0.9; the AUC value for the 0-7 DSO range was 0.88 (Table 1

Young et al., 2020

and <u>Figure 1</u>). Performance values for the Veritor test compared to the Lyra Assay were analyzed by number of symptoms reported by participants during sample collection. As shown in <u>Table 2</u>, PPA point estimates were higher for the Veritor test when stratified by \geq 2 symptoms versus 1 symptom for both the 0-5 DSO range (88.0% and 66.7%, respectively) and the 0-6 DSO range (88.9% and 57.1%, respectively). In addition, stratification of Lyra Ct scores (for the 38 positive reference specimens represented in the entire 0-7 DSO range) by 1 versus \geq 2 symptoms showed non-overlapping distributions, with the 1 symptom Ct score distribution shifted towards higher Ct values (<u>Figure 2a</u>). The mean Ct value for the 1 symptom group (25.56), although not statistically different (p=0.077) from the \geq 2 symptom mean Ct value (22.10), showed a trend towards having a higher mean Ct by approximately 3 cycles, an order of magnitude (Figure 2b).

Eight of the nine false negative specimens by the Veritor test were from participants that had Lyra assay Ct values, which were greater than the mean Lyra Ct value (22.74); the ninth fell just below the mean value (Ct score of 22.04) (Figure 3a). The mean Ct value for Lyra assay results matched with the 29 true positive Veritor test results (20.76; standard deviation of 4.21) was significantly lower than the Lyra assay mean Ct value matched with the nine Veritor test negative discordant results (29.12; standard deviation of 4.11) (mean difference of 8.36; p-value ≤0.001; 2-tailed t-test; 95% CI: 4.95, 11.77) (Figure 3b) . MAX PCR assay testing showed a positive result for only two of the nine Veritor test negative discordant results (Table 3). From the remaining seven discordants, six were associated with a negative MAX assay result and one was associated with an unresolved result (no detection of internal control in the MAX assay).

Young et al., 2020

<u>Figure 4</u> shows the PPV, NPV, and accuracy associated with the Veritor test by DSO range. As shown, PPV values for the Veritor test were 100%, for the 0-1 through 0-5 DSO ranges. The single Veritor test positive discordant result for the Veritor test that occurred in the 0-6 DSO group resulted in a PPV point estimates of 96.6% and 96.7% for the 0-6 and 0-7 DSO ranges, respectively. The NPV values for the 0-1 to 0-6 DSO groups ranged from 96.8 to 97.2. At 0-7 DSO, the NPV was 95.9.

Study 2 (Veritor/Sofia test comparison study)

Participant reconciliation, demographics, and COVID-19 symptomology

From 377 participants, four specimen sets were removed due to inclusion/exclusion criteria and 16 were removed due to non-compliant specimens or invalid test results; 361 evaluable specimens were utilized for this study (<u>Figure S1b</u>). The mean and median age of the participants (45.3 and 44 years, respectively) were similar. Fever, cough, headache, sore throat, and shortness of breath were the five most common symptoms reported (Table S2).

Veritor test performance and discordant reconciliation

The PPA, NPA, and OPA for the Veritor test compared to the Sofia test using specimens at the 0-5 DSO range were 97.4 (95% CI: 86.5, 99.5), 98.1 (95% CI: 96.0, 99.1), and 98.1 (95% CI: 96.1, 99.1) (<u>Table 4</u>). Of the seven discordant results, one was Veritor negative/Sofia positive and was positive by the Lyra assay; six were Veritor positive/Sofia negative, with 5 being positive by the Lyra assay and one being negative by the Lyra assay.

Young et al., 2020

DISCUSSION (1,300 words)

The Veritor test was required to achieve ≥80% PPA relative to the reference standard (with at least 30 positive specimens by reference) in order to be considered acceptable for FDA-EUA. The Veritor test showed 83.9% and 82.4% PPA for specimens from COVID-19 symptomatic participants that were 0-5 and 0-6 DSO, respectively. In addition, the AUC values for the 0-1 through the 0-6 DSO ranges were excellent (ranging from 0.91-0.94). The results presented here suggest that the Veritor test should be effective in settings that would benefit from POC testing (e.g. decentralized health care settings) in order to classify 0-5 or 0-6 DSO individuals as positive or negative for SARS-CoV-2 infection to support patient management.

Discordant analysis for the 0-1 DSO through 0-6 DSO specimens revealed one false negative result (Participant D from <u>Table 3</u>) that was associated with a high (34.02) Ct value for the MAX assay. Interestingly, Participant D had a positive SOC serology result (both IgM and IgG), suggesting that the individual likely had a DSO greater than three. The nasal specimen from participant F had no detectable internal control (RNAse P gene), suggesting a lack of integrity for this specimen. The remaining four participants (A, B, C, and E) had nasal specimens that were negative by the MAX assay, agreeing with the Veritor test. The false-positive (participant G) Veritor test result had a line value that was close to the positive cutoff and was therefore a low positive.

Here the Veritor test had ≥96.0% PPV and NPV values for detection of the SARS-CoV-2 nucleocapsid antigen at all DSO ranges tested. Plotted values demonstrate the dependence of Veritor test NPV on disease prevalence (Table S3). Reflex testing (e.g. PCR-based testing) may

Young et al., 2020

be appropriate following a negative Veritor test result depending on the pretest probability and level of certainty required for patient management given medical history and future clinical action.

Discordant analysis for study 2 was performed using the Lyra assay and resulted in five Lyra and Veritor positive/Sofia negative, one Lyra and Sofia positive/Veritor negative, and one Veritor positive/Lyra and Sofia negative result. For the latter result, the apparent false positive was associated with a Veritor test value that was close to the positive cutoff; this low positive was the lowest positive Veritor value observed in study 2.

PCR-based assays for diagnostic applications are typically highly sensitive for detecting target analyte relative to other diagnostic methods. However, recent results challenge whether this is always advantageous in all diagnostic settings. Bullard et al. (2020) and Wolfel et al. (2020) recently showed PCR-positive results at time points corresponding with negative culture-based testing for active SARS-CoV-2. Importantly, this discrepancy between testing methods seems to emerge around 6-8 DSO.[21, 22] In addition, Wolfel and colleagues show that the presence of sgRNA, a molecular marker for replicating SARS-CoV-2 virus, peaks around day 3-4 DSO, and then decreases drastically by day 6-7 DSO.[22] Finally, antigen-based test accuracy improves significantly when specimens associated with reference PCR values of 31-40 Ct are removed from analysis and only specimens matched with reference values of ≤30 Ct are included.[10] Eight of the nine false-negative Veritor test results here were matched with Lyra assay Ct values that were above the mean Ct value for the 38 Lyra assay positive results (four were approximately ten cycles above). This, combined with the significant difference in Lyra-matched

Young et al., 2020

Ct values for the 29 Veritor test true positive and 9 Veritor test false negative specimens, suggests that Veritor-to-Lyra concordance is indirectly proportional to the Lyra assay Ct score.

While PCR-based testing is sensitive for target detection, other testing modalities (such as antigen-based testing) may also be informative and may help clinicians determine the peak time frame during which infections are transmissible. However, more data is needed to establish the efficacy of antigen-based tests, such as Veritor or Sofia, for identifying contagious individuals—especially in the asymptomatic population. The Veritor and Sofia tests are currently only authorized for individuals suspected of having a SARS-CoV-2 infection at 0-5 DSO. In addition, the high level of agreement observed between the Veritor and Sofia tests as the tests is consistent with reported, similar limits of detection for SARS-CoV-2.[15, 16]

The difference in EUA labeled sensitivity for Sofia (96.7%) vs Veritor (84%) was not supported by this study, probably due to spectrum differences in patient populations in this study versus the Sofia EUA study. The patient population chosen for this study was intended to reflect the performance of the Veritor test in clinical settings where decentralized point-of-care testing such as antigen testing would be most appropriate. The study data presented here included a large proportion of specimens collected from clinical settings (such as drive-through testing, tents, and outpatient clinics), largely include individuals with milder severity illness, compared with study populations that have been used to generate sensitivity estimates for EUA antigen tests where enrollment included Emergency Department patients and hospitalized patients. Several publications have demonstrated an association between severe disease and higher viral loads which could inflate antigen test sensitivity performance estimates when compared to

Young et al., 2020

performance estimates generated in patients with milder disease. [23-27] The finding in this study of an observed Ct score shift for subjects with 1 symptom vs \geq 2 symptoms also supports the possibility that there may even be differences in viral load according to disease severity even amongst patients with milder disease. Analyses here (Table 2 and Figure 2) suggest that \geq 2 symptoms lead to a higher PPA than 1 symptom alone, which is reflected by a trend towards lower Ct scores (higher viral load) for specimens from participants with \geq 2 symptoms.

Limitations

This study had some limitations. First, the Veritor test was performed on nasal swab specimens; however, the Lyra assay was performed on either NP (or OP) swab specimens per FDA-EUA requirements. Other EUA submissions (the LumiraDx SARS-CoV-2 Ag Test ["Luminar test"] and the Abbott BinaxNOW COVID-19 Ag CARD ["Abbott test"]) utilized nasal swab specimens for both the antigen test and the reference PCR assay. Furthermore, MAX from the remnant Veritor nasal swab in this report agreed with negative Veritor results in 7 of 9 discordant specimens. Improved PPA for Veritor versus Lyra may have been achieved through the use of paired nasal swab specimens in the EUA study.

The Sofia assay in study 2 was performed on nasal swabs that were collected either with (Table S4) or without (Table S5) a nose blowing step prior to collection. The nose-blowing step was an addition to the Sofia test IFU intended only to reduce the frequency of invalid results, and was not included in order to alter the performance of the Sofia test. Although the n is low for specimens with a pre-nose blowing step in study 2, here, the results suggest that the nose-blowing step did not alter the overall performance of the Sofia test in relation to the Veritor test.

Young et al., 2020

Conclusions

The Veritor test met acceptance criteria for Emergency Use Authorization criteria for antigen testing (≥80% PPA point estimate) for the 0-5 and 0-6 DSO ranges in a population of 251 subjects. The 0-1 through 0-6 DSO ranges had AUC values ≥0.90, suggesting that it is a reliable point of care test. Results here suggest that number of symptoms may influence the sensitivity of antigen-based POC testing. In additional testing, Veritor returned 43 positive results and Sofia returned 37 positive results from a population of 361 subjects. The speed (15 minute run time) and performance of antigen tests for SARS-CoV-2 detection should facilitate rapid and reliable results for COVID-19 diagnosis. This study generated point estimates from a population that represents the most appropriate intended use population and thus can be used to inform proper patient management. In addition, it should have a significant impact in decentralized healthcare settings where requirements for larger-scale PCR-based tests are harder to meet or result in extended turn-around-times.

Young et al., 2020

FUNDING

This study was funded by Becton, Dickinson and Company; BD Life Sciences—Integrated

Diagnostics Solutions. Non-BD employee authors received research funds as part of this work.

CONFLICTS OF INTEREST

The authors disclose the following conflicts of interest:

CRD, CF, KE, JCA, HR, and CKC are employees of Becton, Dickinson and Company; SY,

None; CC, None; AM, None; CGF, None; CB, None; JA, None; RA, CEO and PI of

Comprehensive Clinical Research LLC

ACKNOWLEDGEMENTS

The authors would like to thank Richard Anderson, Dave Kurisko, Edith Torres-Chavolla,

Katherine Christensen, and Devin S. Gary (Becton, Dickinson and Company, BD Life Sciences

– Diagnostic Systems), for their input on the content of this manuscript and editorial assistance.

The authors also thank Stanley Chao and Aojun Li (Becton, Dickinson and Company, BD Life

Sciences – Diagnostic Systems) for statistical support. The individuals acknowledged here have

19

no additional funding or additional compensation to disclose.

REFERENCES

- Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) - Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff. Version May 11, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policycoronavirus-disease-2019-tests-during-public-health-emergency-revised.
- 2. Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. Journal of Medical Virology **2020**; 92(6): 538-9.
- 3. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv **2020**: 2020.02.11.20021493.
- 4. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert review of molecular diagnostics **2020**; 20(5): 453-4.
- 5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
- 6. Reusken CBEM, Broberg EK, Haagmans B, et al. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Eurosurveillance **2020**; 25(6).
- 7. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nature Biotechnology **2020**; 38(5): 515-8.
- 8. World Health Organization. Global Research Collaboration for Infectious Disease Preparedness. COVID 19: Public Health Emergency of International Concern (PHEIC). Global Research and Innovation Forum: Towards a Research Roadmap. 02/11/2020-02/12/2020. https://www.who.int/blueprint/priority-diseases/key-action/Global Research Forum FINAL VERSION for web 14 feb 2020.pdf?ua=1.

- 9. Che X-Y, Hao W, Wang Y, et al. Nucleocapsid Protein as Early Diagnostic Marker for SARS. Emerging infectious diseases **2004**; 10(11): 1947-9.
- 10. Diao B, Wen K, Chen J, et al. Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein. medRxiv **2020**: 2020.03.07.20032524.
- 11. Bojkova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature **2020**; 583(7816): 469-72.
- 12. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (New York, NY) **2003**; 300(5624): 1394-9.
- 13. Burbelo PD, Riedo FX, Morishima C, et al. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. medRxiv **2020**.
- 14. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Radiology **2015**; 277(3): 826-32.
- 15. BD Veritor™ System for Rapid Detection of SARS-CoV-2 [package insert, EUA]. Becton, Dickinson and Company, Sparks-Glencoe, MD; 2020.
- 16. Sofia® SARS Antigen FIA [package insert, EUA]. Quidel Corporation. San Diego, CA; 2020.
- 17. Lyra® SARS-CoV-2 Assay [package insert, EUA]. Quidel Corporation. Athens, OH; 2020.
- 18. SARS-CoV-2 Reagents for the MAXTM System [package insert, EUA]. Becton, Dickinson and Company, Sparks-Glencoe, MD; 2020.
- 19. U.S. Food and Drug Administration. In Virtor Diagnostics EUAs. Antigen Template for Manufacturers. May 11, 2020. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas.
- 20. Alberg AJ, Park JW, Hager BW, Brock MV, Diener-West M. The use of "overall accuracy" to evaluate the validity of screening or diagnostic tests. Journal of general internal medicine **2004**; 19(5 Pt 1): 460-5.

- 21. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America **2020**.
- 22. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature **2020**; 581(7809): 465-9.
- 23. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19. Viral Immunology 2020.
- 24. Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infectious Diseases **2020**; 20(6): 656-7.
- 25. Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. The Lancet Respiratory Medicine **2020**.
- 26. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. The Journal of clinical investigation **2020**.
- 27. Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Critical Care **2020**; 24(1): 170.

FIGURE LEGENDS

Figure 1. Veritor test performance results are plotted as a receiver-operator curve with sensitivity (corresponding to positive percent agreement) on the y-axis and 1-specificity (corresponding to 1-negative percent agreement) on the x-axis. Five lines, representing a 0-1 DSO, a 0-3 DSO, a 0-5 DSO, a 0-6 DSO, and a 0-7 DSO are shown. Also shown are the area under the curve values. **Abbreviations:** POC, point of care; DSO, days from symptom onset; AUC, area under the curve

Figure 2. (a) The distribution of Ct values corresponding to the 38 specimens that were positive by the Lyra assay (from specimens collected from participants, 0-7 DSO) following stratification by number of symptoms. Ct score distribution for specimens matched to 1 symptom is shown in blue while those matched to≥2 symptoms are shown in orange; the pink color indicates blue/orange overlap (b) The mean Ct values (and standard deviation) are shown for the 1 symptom specimens (n=31; mean=22.10, standard deviation=5.63) and the ≥2 symptom specimens (n=7; mean=25.56, standard deviation=3.90). Two-tailed t-test analysis revealed a non-significant difference between the means (p-value=0.077; mean difference of 3.46; [95% CI: -0.43, 7.36]).

Figure 3. (a) The distribution of Ct values corresponding to the 38 specimens that were positive by the Lyra assay (from specimens collected from participants, 0-7 DSO). Each bar represents a "bin" of Ct ranges with (from left to right) valuing (i) 13.75-16.25; n=4 (ii) 16.25-18.75; n=7 (iii) 18.75-21.25; n=9 (iv) 21.25-23.75; n=1 (v) 23.75-26.25; n=6 (vi) 26.25-28.75; n=5 (vii) 28.75-31.25; n=2 (viii) 31.25-33.75; n=3 (ix) 33.75-36.25; n=1). Plotted along the fitted distribution line are the 29 true positive Veritor results (orange circles) and the nine participant designations (letters superimposed onto blue circles), corresponding to those in <u>Table 2</u>, that represent the Veritor false negative results matched to Lyra assay Ct value. (b) The mean Ct values (and standard deviation) are shown for the 29 (20.76 and 4.21, respectively) true positive and the 9 (29.12 and 4.11, respectively) false negative Veritor test results. Two-tailed t-test analysis revealed a significantly higher mean Lyra assay Ct value for specimens matched to the 9 Veritor test false negative results compared to those matched to the 29 true positive results (p<0.001; mean difference of 8.36; [95% CI: 4.95, 11.77]).

Figure 4. PPV, NPV, and test accuracy as a function of DSO for SARS-CoV-2 detection by the Veritor test. The point estimates for the three test values are plotted along the y-axis as percentages and the seven DSO ranges (0-1 to 0-7) reside along the x-axis. The SARS-CoV-2 prevalence value at each, respective, DSO range (based on positive reference results) was utilized for calculations and are as follows: 0-1 (21.1%), 0-2 (21.1%), 0-3 (14.7%), 0-4 (14.3%), 0-5 (13.7%), 0-6 (13.9%), and 0-7 (14.6%). Abbreviations: PPV, positive predictive value; NPV, negative predictive value; DSO, days from symptom onset.

TABLES TABLE 1

Table 1. Veritor test performance at one through seven DSO

Performance ^a	1 DSO	2 DSO	3 DSO	4 DSO	5 DSO ^b	6 DSO	7 DSO
PPA %, [95% CI]	87.5 [52.9, 97.8]	85.0 [64.0, 94.8]	81.8 [61.5, 92.7]	85.2 [67.5, 94.1]	83.9 [67.4, 92.9]	82.4 [66.5, 91.7]	76.3 [60.8, 87.0]
NPA %, [95% CI]	100 [88.6, 100]	100 [95.1, 100]	100 [97.1, 100]	100 [97.7, 100]	100 [98.1, 100]	99.5 [97.4, 99.9]	99.5 [97.4, 99.9]
OPA %, [95% CI]	97.4 [86.5, 99.5]	96.8 [91.1, 98.9]	97.3 [93.3, 99.0]	97.9 [94.7, 99.2]	97.8 [94.9, 99.1]	97.1 [94.2, 98.6]	96.0 [92.8, 97.8]
AUC	0.94	0.93	0.91	0.93	0.92	0.91	0.88
True positives	7	17	18	23	26	28	29
False negatives	1	3	4	4	5	6	9
True negatives	30	75	127	162	195	210	212
False positives	0	0	0	0	0	1	1
Total	38	95	149	189	226	245	251

Abbreviations: DSO, days from symptom onset; PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement; AUC, area under the curve

^aPerformance of Veritor test compared to the Lyra assay as reference

^bThe Veritor test is FDA-authorized for detection of SARS-CoV-2 only in individuals that are 0-5 DSO

Veritor SARS-CoV-2 POC test Young et al., 2020

TABLE 2

Table 2. Veritor test performance by number of symptoms at 0-5 and 0-6 DSO

·	Number of symptoms						
'	0-5	DSO	0-6	DSO			
Performance ^a	1	≥2	1	≥2			
PPA %, [95% CI]	66.7 [30.0, 90.3]	88.0 [70.0, 95.8]	57.1 [25.0, 84.2]	88.9 [71.9, 96.1]			
NPA %, [95% CI]	100 [95.7, 100]	100 [96.6, 100]	100 [95.8, 100]	99.2 [95.6, 99.9]			
OPA %, [95% CI]	97.8 [92.3, 99.4]	97.8 [93.7, 99.2]	96.8 [91.0, 98.9]	97.4 [93.4, 99.0]			
True positives	4	22	4	24			
False negatives	2	3	3	3			
True negatives	85	110	87	123			
False positives	0	0	0	1			
Total	91	135	94	151			

Abbreviations: DSO, days from symptom onset; PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement; AUC, area under the curve

^aPerformance of Veritor test compared to the Lyra assay as reference

TABLE 3

Table 3. Discordant analysis for specimens associated with disagreement between Veritor test and Lyra assay

Participant	DSO	Lyra result (Ct value)	Veritor result	MAX result (Ct value)	Serology result ^a
Α	One	POS (27.21)	NEG ^b	NEG	n/a
В	Two	POS (27.60)	NEG ^b	NEG	n/a
С	Two	POS (31.90)	NEG ^b	NEG	n/a
D	Three	POS (25.72)	NEG	POS (34.02)	POS: IgM and IgG
Е	Five	POS (27.56)	NEG ^b	NEG	n/a
Day 0-5: fiv	ve FN resu	lts			
F	Six	POS (22.04)	NEG	UNR ^c	n/a
G	Six	NEG (n/a)	POS	NEG	n/a
Day 0-6: si	x FN resul	ts and one FP			
Н	Seven	POS (31.84)	NEG	POS (32.72)	POS: IgM and IgG
I	Seven	POS (33.57)	NEG ^b	NEG	POS: IgM and IgG
J	Seven	POS (34.60)	NEG ^b	NEG	n/a
Day 0.7. m	ENI	L ED			

Day 0-7: nine FN and one FP

Abbreviations: DSO, days from symptom onset; AU, arbitrary units; POS, positive; NEG, negative; FN, false negative; UNR, unresolved; FP, false positive

^aIndicates serology testing done as part of standard of care prior to study-related activities

^bIndicates agreement of Veritor test with MAX assay for a negative result for SARS-CoV-2

^cIndicates a negative RNAseP result (internal control) in the MAX assay suggesting no presence of human material on the nasal swab

TABLE 4

Table 4. Agreement between Veritor and Sofia for detection of SARS-CoV-2

	· -
PPA %, [95% CI]	97.4 (86.5, 99.5)
NPA %, [95% CI]	98.1 (96.0, 99.1)
OPA %, [95% CI]	98.1 (96.1, 99.1)
Veritor (+)/Sofia(+)	37
Veritor (-)/Sofia (+)	1 ^a
Veritor (+)/Sofia (-)	6 ^b
Veritor (-)/Sofia(-)	317

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement

^aThe 1 negative Veritor test/positive Sofia test results were positive by Lyra assay discordant testing

^bOf the 6 positive Veritor test/negative Sofia test results 5 were positive and 1 was negative by Lyra assay discordant testing

FIGURES FIGURE 1

Figure 1.




FIGURE 2

Figure 2a.




Figure 2b.




FIGURE 3

Figure 3a.




Figure 3b.





FIGURE 4

Figure 4. Veritor test accuracy, PPV, and NPV across 1-7 DSO



Supplemental Material TABLE S1

Table S1. Study 1 (EUA) participant demographics (N=260)

Table S1. Study 1 (EUA) participant demographics (N=	=260) Value
Age, years Mean	44.7
SD Madien	16.6
Median	43.0
Min	18
Max	90
Gender, % (n)	0.4.0 (4.07)
Female	64.2 (167)
Race, % (n)	0.0 (40)
Asian	6.2 (16)
Black	10.4 (27)
White	55.87 (145)
Other	7.3 (19)
Ethnicity, % (n)	
Hispanic or Latino	40.4 (105)
Not Hispanic or Latino	55.8 (145)
Not reported	3.8 (10)
Symptoms, % (n)	
Cough	42.7 (111)
Muscle pain	37.3 (97)
Headache	36.9 (96)
Sore throat	35.4 (92)
Fever	30.0 (78)
Shortness of breath	20.0 (52)
Chills	16.9 (44)
New loss of taste or smell	4.6 (12)
Other ^a	25.8 (67)
Collection site	
All Sites ^b	21
Drive through/tent (% of total sites)	38.1% (8/21)
Total specimens collected	67
% REF positive of total collected	14.9% (10/67)
Outpatient clinic (% of total sites)	38.1% (8/21)
Total specimens collected	51
% REF positive of total collected	17.6% (9/51)
Research clinic (% of total sites)	19.0% (4/21)
Total specimens collected	72
% REF positive of total collected	22.2% (16/72)
Skilled nursing facility (% of total sites)	4.8% (1/21)
Total specimens collected	70
% REF positive of total collected	4.3% (3/70)
Overall positivity rate	14.6% (38/260)
	/5 (56/200)
Mean DSO	3.2
Median DSO	3.0
Mode DSO	2.0
Although the control of the MINI printers	

Abbreviations: SD, standard deviation; MIN, minimum; Max, maximum; DSO, days from symptom onset; REF, reference test

 $[{]f a}$ "Other" symptoms include gastrointestinal issues, fatigue, chest pain, rhinorrhea, and nasal congestion

^bCollection sites reside in the following states: Arizona, California, Florida (7), Georgia, Iowa, Louisiana, North Carolina, Nevada (2), Ohio (3), South Carolina, Texas, Utah

TABLE S2

Table S2. Study 2 (Veritor vs Sofia comparison) participant demographics (N=277)

demographics (N=277)	
Age, years	Value
Mean	45.3
SD	16.4
Median	44
Min	18
Max	98
Gender, % (n)	
Female	59.7 (225)
Race, % (n)	-
Asian	0.3 (1)
Black	15.9 (60)
White	69.8 (263)
Other	14.1 (53)
Ethnicity, % (n)	
Hispanic or Latino	66.0 (249)
Not Hispanic or Latino	34.0 (128)
Not reported	
Symptoms, % (n)	
Cough	66.0 (210)
Muscle pain	34.0 (202)
Headache	55.7 (254)
Sore throat	53.6 (198)
Fever	67.4 (128)
Shortness of breath	52.5 (51)
Chills	37.1 (140)
New loss of taste or smell	17.5 (66)
Other ^a	45.3 (171)
Collection site	•
All Sites	5
Drive through/tent (% of total sites)	20.0 (1/5)
Veritor positivity rate (%)	11.1 (1/9)
Sofia positivity rate (%)	11.1 (1/9)
Outpatient clinic (% of total sites)	40.0 (2/5)
Veritor positivity rate (%)	6.7 (4/60)
Sofia positivity rate (%)	5.0 (3/60)
Research clinic (% of total sites)	40.0 (2/5)
Veritor positivity rate (%)	12.3 (38/308)
Sofia positivity rate (%)	11.0 (34/308)
Overall (either test) positivity rate	11.7 (44/377)
Mean DSO	3.0
Median DSO	3.0
Mode DSO	4.0
mode DOO	4.∪

Abbreviations: SD, standard deviation; MIN, minimum; Max, maximum; DSO, days from symptom onset; REF, reference test

a"Other" symptoms include shaking, gastrointestinal issues, fatigue, chest pain, rhinorrhea, and nasal congestion

TABLE S3

Table S3. Positive and negative predictive values for the Veritor test compared to the Lyra Assay

	Prevalence (%) ^a							
0-5 DSO	1.0	2.0	5.0	10.0	15.0	20.0	25.0	30.0
PPV (%, [95% CI])	100 [33.2, 100]	100 [50.1, 100]	100 [72.1, 100]	100 [84.5, 100]	100 [89.7, 100]	100 [92.5, 100]	100 [94.2, 100]	100 [96.2, 100]
NPV (%, [95% CI])	98.8 [99.7, 99.9]	99.7 [99.3, 99.9]	99.2 [98.3, 99.7]	98.2 [96.4, 99.4]	97.2 [94.4, 99.0]	96.1 [92.2, 98.7]	94.9 [89.9, 98.2]	93.5 [86.6, 97.0]

Abbreviations: DSO, days from symptom onset; PPV, positive predictive value; CI, confidence interval; NPV, negative predictive value

^aPrevalence of SARS-CoV-2 among the 0-5 DSO participants

TABLE S4

Table S4. Agreement between Veritor and Sofia (only collection involving nose blowing prior to nasal swab collection) for detection of SARS-CoV-2

PPA %, [95% CI]	100 (56.6, 100)
NPA %, [95% CI]	98.5 (91.8, 99.7)
OPA %, [95% CI]	98.6 (92.3, 99.7)
Veritor (+)/Sofia(+)	5
Veritor (-)/Sofia (+)	0
Veritor (+)/Sofia (-)	1 ^a
Veritor (-)/Sofia(-)	64

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement

^aThe 1 positive Veritor test/negative Sofia test results were positive by Lyra assay discordant testing

TABLE S5

Table S5. Agreement between Veritor and Sofia (nose blowing not included prior to nasal swab collection) for detection of SARS-CoV-2

PPA %, [95% CI]	97.0 (84.7, 99.5)
NPA %, [95% CI]	98.2 (95.8, 99.2)
OPA %, [95% CI]	98.0 (95.8, 99.1)
Veritor (+)/Sofia(+)	32
Veritor (-)/Sofia (+)	1 ^a
Veritor (+)/Sofia (-)	5 ^b
Veritor (-)/Sofia(-)	267

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement

^aThe 1 negative Veritor test/positive Sofia test results were positive by Lyra assay discordant testing

^bOf the 5 positive Veritor test/negative Sofia test results 4 were positive and 1 was negative by Lyra assay discordant testing

FIGURE S1






Figure S1b.




Figure S1. (a) Reconciliation during enrollment of swab specimens from participants, ≥18 years of age, with signs or symptoms of COVID-19 for study 1. **Abbreviations:** ID, identification; DSO, days from symptom onset (b) Reconciliation during enrollment of swab specimens from participants, ≥ 18 years of age, with signs or symptoms of COVID-19 for study 2.

Abbreviations: DSO, days from symptom onset